Cosmos Health CEO Greg Siokas Acquires Over 3.39 Million Shares, Expresses Strong Confidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: Globenewswire
- Share Acquisition: Cosmos Health CEO Greg Siokas acquired 301,101 shares between November 19 and 28, 2025, increasing his total holdings to 6,459,985 shares, demonstrating strong confidence in the company's future prospects.
- Record Performance: The company reported record-breaking Q3 2025 results with all-time-high quarterly revenue, gross profit, and gross margins, driven by robust growth across core business segments, and expects this momentum to continue into Q4, further solidifying its market position.
- Global Expansion Plans: Siokas indicated that despite valuation pressures, he remains confident in Cosmos Health's potential for global expansion and innovative product pipelines, planning to continue supporting the company's strategic objectives.
- Investor Confidence: Siokas's share acquisition not only reflects his optimistic outlook for the company’s future but may also enhance investor confidence in Cosmos Health, potentially leading to positive impacts on its stock price.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
Continue Reading
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
Continue Reading